Protracted chronic and acute rhinitis: approach to therapy

Abstract

Introduction. The prevalence of acute and chronic rhinitis determines the socio-economic side of the issue and requires effective treatment and improvement of patients’ quality of life.Aim. To study the effectiveness of the Rinofluimucil® in patients with acute and chronic catarrhal rhinitis at the outpatient stage of treatment.Materials and methods. The study was conducted in a group of 82 patients aged 18 to 59 years (average age 37,7 ± 13,1 years) diagnosed with acute rhinitis and chronic catarrhal rhinitis. Two groups were identified: the main group (21 patients with acute rhinitis and 20 patients with chronic rhinitis) and the control group (20 patients with acute rhinitis and 21 patients with chronic rhinitis). The control group received elimination and symptomatic therapy, the main group received endonasal monotherapy with Rinofluimucil®, one dose 3 times a day for 7 days. The effectiveness of the treatment was determined by the dynamics of subjective and objective symptoms.Results and discussion. In patients with acute rhinitis in the main group, the assessment of the amount of nasal discharge and concentration of attention changed by 12,3 and 10,5 times, respectively. In patients with chronic rhinitis, the assessment of the amount of nasal discharge and concentration in the main group changed by 3,3 and 2,6 times, respectively. Restoration of mucociliary clearance to normal with the use of the Rinofluimucil® was observed in patients with both acute rhinitis (18,1 ± 0,4 s) and chronic catarrhal rhinitis (21,3 ± 0,2 s). According to the PARM data, by the 7th day of observation there was an improvement in the average value of the total volumetric flow of nasal breathing in patients with acute and chronic rhinitis in the main group by 1,9 and 2 times, respectively.Conclusions. The data obtained indicate the importance of using the Rinofluimucil® in patients with acute and chronic rhinitis in clinical practice.